Intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents is the mainstay of treatment for multiple retinal diseases, including neovascular age-related macular degeneration (AMD), diabetic macular edema, and macular edema from retinal vein occlusions. Here, VEGFA is linked to wet macular degeneration.